Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded at Wall Street Zen

Posted by Stanley Muller on Nov 11th, 2026

Wall Street Zen upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) from a strong sell rating to a hold rating in a report released on Sunday,Wall Street Zen reports.

A number of other brokerages have also issued reports on LXRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, October 21st. Zacks Research cut Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Cantor Fitzgerald started coverage on Lexicon Pharmaceuticals in a research report on Monday, September 28th. They set an “overweight” rating and a $8.00 price target for the company. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $5.80.

View Our Latest Research Report on Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Stock Up 2.2%

Shares of NASDAQ LXRX opened at $1.86 on Friday. The company has a quick ratio of 10.56, a current ratio of 10.62 and a debt-to-equity ratio of 0.32. Lexicon Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $2.68. The company has a fifty day moving average price of $1.80 and a 200 day moving average price of $1.89.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. The firm had revenue of $11.25 million for the quarter, compared to the consensus estimate of $4.14 million. Lexicon Pharmaceuticals had a negative return on equity of 35.76% and a negative net margin of 161.80%. As a group, equities analysts expect that Lexicon Pharmaceuticals will post -0.16 EPS for the current year.

Insider Buying and Selling

In other Lexicon Pharmaceuticals news, CEO Michael Exton purchased 30,064 shares of the business’s stock in a transaction on Friday, November 6th. The shares were purchased at an average cost of $1.66 per share, with a total value of $49,906.24. Following the transaction, the chief executive officer directly owned 328,496 shares of the company’s stock, valued at $545,303.36. This represents a 10.07% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.00% of the stock is owned by company insiders.

Institutional Trading of Lexicon Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of LXRX. Squarepoint Ops LLC acquired a new position in Lexicon Pharmaceuticals during the second quarter valued at approximately $28,000. CTC Alternative Strategies Ltd. acquired a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $27,000. Pictet Asset Management Holding SA acquired a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter worth approximately $41,000. Bank of New York Mellon Corp raised its stake in shares of Lexicon Pharmaceuticals by 43.6% during the 1st quarter. Bank of New York Mellon Corp now owns 27,459 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 8,335 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter worth approximately $66,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Key Stories Impacting Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

Positive Sentiment: CEO Michael Exton bought 30,064 shares at an average $1.66, increasing his stake by about 10%. Insider purchases can signal confidence in the company’s prospects. Insider purchase report
Positive Sentiment: Citigroup raised its price target from $3.10 to $3.40 and maintained a Buy rating, a more optimistic analyst view that may support investor sentiment. Citigroup ratings
Positive Sentiment: New investigator-led research reported that sotagliflozin reduced thrombus formation in a crossover study and acutely lowered myocardial work in living heart tissue from patients with hypertrophic cardiomyopathy. These findings provide mechanistic evidence for the drug, but do not establish clinical benefit; SONATA-HCM topline results are expected in Q1 2027. Lexicon research announcement
Neutral Sentiment: A report says short interest totaled zero shares as of November 10, despite describing this as an increase. The conflicting wording makes the figure difficult to interpret as a clear trading signal.
Neutral Sentiment: Recent analyst views remain mixed: the report cites three Buy ratings, one Hold and one Sell, with an overall consensus Hold. Analyst insights

About Lexicon Pharmaceuticals

(Get Free Report)

Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. Founded in 1995 as Lexicon Genetics, the company uses drug discovery and development research to create medicines for serious diseases, with a focus on areas of unmet medical need. Its commercial product, Inpefa (sotagliflozin), is approved in the United States to reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure. Lexicon also develops investigational medicines, including candidates studied for neuropathic pain and other conditions.